Global X Artificial Intelligence & Technology ETF vs Zimmer Biomet Holdings Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.82, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AIQ | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $107.71 |
52-Week Low | $43.88 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
AIQ (Global X Artificial Intelligence & Technology ETF) trades at $63.77, up 0.41% with strong bullish momentum. Technical indicators show the stock above key moving averages with RSI suggesting mild overbought conditions. Recent news highlights AIQ's outperformance versus the Nasdaq, gaining 25% while attracting attention as a diversified AI play beyond semiconductor stocks. The ETF's systematic rebalancing approach positions it well for the evolving AI investment landscape.
AIQ offers exposure to the growing artificial intelligence sector with reduced single-stock risk. Key catalysts include upcoming AI company IPOs and federal quantum computing funding. Risks include thematic ETF volatility and premium fees compared to broader indices. The stock's proximity to resistance levels near $64 suggests potential near-term consolidation before further upside.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →